A tiny peptide from scorpion venom, given through the nose, significantly reduced long-lasting pain and spinal cord inflammation in a mouse pain model.
10-day nasal treatmentDaily intranasal dosing of a 4-amino-acid scorpion peptide reduced chronic pain behavior in mice
What the researchers found
Intranasal AaTs-1 significantly reduced pain hypersensitivity and neuroinflammation while preventing morpho-functional alterations in spinal cord neurons and glial cells in a formalin-induced chronic pain model.
Why it matters
Chronic pain remains poorly managed, and venom-derived peptides represent a novel therapeutic avenue. The intranasal delivery route is particularly promising as it bypasses the blood-brain barrier, potentially offering a non-invasive way to deliver peptide therapeutics to the central nervous system.
The numbers in context
- AaTs-1 is a tetrapeptide (4 amino acids) from Androctonus australis scorpion venom
- Administered intranasally for 10 days
- Abolished mechanical allodynia and thermal hyperalgesia
- Reversed hyperactivation of spinal nociceptive-specific neurons
- Partially restored spinal cytokine balance and glial cell phenotypes
How the study worked
Animal study using formalin-induced long-lasting pain hypersensitivity in mice. AaTs-1 was administered intranasally daily for 10 days. Assessed pain responses, cytokine levels, and neuronal/glial changes in the spinal cord.
Who was studied
Mice with formalin-induced long-lasting pain hypersensitivity. Tetrascorpin-1 from Androctonus australis scorpion venom administered intranasally.
What this study cannot tell us
Animal study only — effects in humans unknown; formalin model may not fully represent clinical chronic pain conditions; long-term safety of repeated intranasal peptide delivery not assessed; mechanism of action through FPR-2 needs further confirmation in vivo.
How to read the evidence
Preclinical animal study providing early proof-of-concept. Promising results but far from clinical applicability without human trials.
When this study was published
Published in 2025, representing cutting-edge venom peptide research.
The bigger picture
Venom-derived peptides are an expanding frontier in pain research. This study adds to evidence that nature-derived peptides, combined with innovative delivery routes like intranasal administration, could offer alternatives to opioid-based pain management.
Questions still open
- Would AaTs-1 be effective in other chronic pain models, such as neuropathic pain?
- What is the optimal dose and duration for intranasal peptide delivery in larger animals or humans?
- Could the peptide be modified to improve its stability and potency for clinical development?
Common questions
Is it safe to use scorpion venom as medicine?
Why deliver pain medication through the nose?
Read the original research
Antinociceptive and neuromodulatory effects of the scorpion venom tetrapeptide tetrascorpin-1 in a long-lasting pain hypersensitivity model in mice.
Toxicon : official journal of the International Society on Toxinology, 268, 108611
Citation
Pagano, Salvatore; Limongelli, Rebecca; Moslah, Wassim; Saada, Mohamed-Chiheb; Manzo, Iolanda; Bonsale, Roozbe; Teweldemedhin, Milena Melake; Fusco, Antimo; Guida, Francesca; Belardo, Carmela; Morace, Andrea Maria; Perrone, Michela; Ricciardi, Federica; Pierretti, Gorizio; Vastarella, Maria Giovanna; Infantino, Rosmara; Srairi-Abid, Najet; Maione, Sabatino; Palazzo, Enza; Luongo, Livio. (2025). Antinociceptive and neuromodulatory effects of the scorpion venom tetrapeptide tetrascorpin-1 in a long-lasting pain hypersensitivity model in mice.. Toxicon : official journal of the International Society on Toxinology, 268, 108611. https://doi.org/10.1016/j.toxicon.2025.108611